Salud financiera de hoja de balance de iBio

Salud financiera controles de criterios 1/6

iBio tiene un patrimonio de los accionistas total de $9.2M y una deuda total de $13.1M, lo que sitúa su ratio deuda-patrimonio en 142.8%. Sus activos y pasivos totales son $34.0M y $24.8M respectivamente.

Información clave

142.8%

Ratio deuda-patrimonio

US$13.14m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$2.79m
Patrimonio	US$9.20m
Total pasivo	US$24.83m
Activos totales	US$34.02m

Actualizaciones recientes sobre salud financiera

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($19.7M) de 0JV0 no cubren sus pasivos a corto plazo ($21.6M).

Pasivo a largo plazo: Los activos a corto plazo de 0JV0 ($19.7M) superan a sus pasivos a largo plazo ($3.3M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de 0JV0 (112.5%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de 0JV0 ha crecido de 0% a 142.8% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: 0JV0 tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: 0JV0 tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 20.9% cada año

Salud financiera de hoja de balance de iBio

Salud financiera controles de criterios 1/6

Información clave

Actualizaciones recientes sobre salud financiera

iBio, Inc. announced delayed annual 10-K filing

iBio Regains Compliance with NYSE American Continued Listing Standards

iBio, Inc. announced delayed annual 10-K filing

Recent updates

iBio, Inc. Announces Directorate Appointments

iBio, Inc., Annual General Meeting, Nov 21, 2024

iBio, Inc. Announces the Appointment of Kristi Sarno as Senior Vice President of Business Development

Texas A&M University System Board of Regents acquired Manufacturing facility located in Bryan, Texas of iBio, Inc. (NYSEAM:IBIO) for $8.5 million.

iBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC

iBio, Inc. announced that it expects to receive $15.068742 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $4.780385 million.

New major risk - Financial position

iBio, Inc. Announces Expansion of its AI-Powered Technology Stack with Launch of ShieldTx

iBio, Inc., Annual General Meeting, Nov 27, 2023

New major risk - Market cap size

iBio, Inc. Appoints Dr. Martin Brenner as CEO

iBio, Inc. Announces the Expansion of Its AI-Powered Technology Stack with the Launch of EngageTx

Third quarter 2023 earnings released: US$0.48 loss per share (vs US$1.42 loss in 3Q 2022)

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

First half 2023 earnings released: US$1.93 loss per share (vs US$1.97 loss in 1H 2022)

iBio, Inc. Appoints Felipe Duran as Interim Chief Financial Officer, Effective as of February 13, 2023

iBio, Inc. Announces Resignation of Robert Lutz, the Chief Financial and Business Officer as an Executive Officer, Effective February 10, 2023

High number of new and inexperienced directors

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

iBio, Inc. to Showcase the RubrYc Discovery Engine During Poster Presentations At Antibody Engineering & Therapeutics Conference 2022

iBio, Inc. Announces Executive Changes

iBio, Inc. Announces the Resignation of Thomas F. Isett as a Member of the Board

iBio, Inc. Appoints William D. (Chip) Clark as Chairman

iBio, Inc., Annual General Meeting, Dec 08, 2022

iBio, Inc. Files a Provisional Patent with the United States Patent and Trademark Office Title 'Epidermal Growth Factor Receptor Variant III Antibodies'

iBio, Inc. announced delayed annual 10-K filing

iBio, Inc. to Report Q4, 2022 Results on Sep 27, 2022

iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate

Third quarter 2022 earnings released: US$0.057 loss per share (vs US$0.036 loss in 3Q 2021)

iBio, Inc. to Report Q3, 2022 Results on May 12, 2022

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

iBio, Inc. to Report Q2, 2022 Results on Feb 14, 2022

iBio, Inc. Shares an Update on Its Lead COVID-19 Vaccine Program, IBIO-202

iBio, Inc Announces Update for its Lead COVID-19 Vaccine Program, IBIO-202, in Light of the Emergence of the Omicron (B.1.1.529) Variant of SARS-CoV-2

First quarter 2022 earnings released: US$0.041 loss per share (vs US$0.047 loss in 1Q 2021)

High number of new directors

iBio, Inc. Provides Revenue Guidance for the First Half, Second Half and Full Year of Fiscal 2022

High number of new directors

iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate

iBio, Inc.(NYSEAM:IBIO) dropped from Russell Microcap Growth Index

Third quarter 2021 earnings released: US$0.036 loss per share (vs US$0.059 loss in 3Q 2020)

iBio, Inc. Reports Successful Covid-19 Vaccine Toxicology Study Results and Announces Next-Gen Covid-19 Vaccine Program

iBio, Inc. and Fraunhofer USA, Inc. Concludes Litigation

Second quarter 2021 earnings released: US$0.044 loss per share (vs US$0.69 loss in 2Q 2020)

Revenue beats expectations

iBio, Inc. Appoints Robert M. Lutz as Chief Financial & Business Officer, Effective March 4, 2021

iBio, Inc. to Report Q2, 2021 Results on Feb 16, 2021

New 90-day high: €1.73

iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer

New 90-day low: €0.88

iBio, Inc. Announces Resignation of Robert L. Erwin as President

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $32.493644 million.

iBio to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins

iBio, Inc. to Report Q1, 2021 Results on Nov 16, 2020

iBio, Inc. Appoints Randy J. Maddux as Chief Operating Officer, Effective December 1, 2020

iBio, Inc. Announces Appointment of Members to Committees

iBio, Inc. Appoints Gary Sender to Its Board of Directors

iBio, Inc. Announces the Appointment of Linda Armstrong to Board of Directors

iBio Regains Compliance with NYSE American Continued Listing Standards

iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming® System

iBio, Inc. announced delayed annual 10-K filing

New 90-day high - €3.12

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera